NCT03350464

Brief Summary

Transcranial magnetic stimulation (TMS) is a procedure that has been shown to improve pain in chronic sufferers. It is a well-tolerated procedure that can be performed on an outpatient basis. It uses a plastic covered coil that sends a magnetic pulse through the skull into the brain and by targeting particular areas in the brain it can be used to help modulate the perception of pain. The study intends to use this technique to treat such a disabling symptom in patients who suffer from Parkinson's Disease (PD). Initially the aim is to study this technique in ten patients who are suffering from pain and have PD. These patients would initially require an MRI scan which allows us to map the brain and target the correct brain areas for the delivery of the stimulation. The stimulation would be performed over ten sessions and the patients would be assessed by a clinician using well recognized clinical tools. It is anticipated that there will be a meaningful improvement in pain. It is also anticipated that TMS is a safe technique to use in patients with PD. The study will be used to help plan a future study that compares TMS with sham technique to prove whether TMS could be an option in the treatment of such a disabling condition.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for not_applicable parkinson-disease

Timeline
Completed

Started Apr 2018

Shorter than P25 for not_applicable parkinson-disease

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 20, 2017

Completed
1 month until next milestone

First Posted

Study publicly available on registry

November 22, 2017

Completed
4 months until next milestone

Study Start

First participant enrolled

April 5, 2018

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 11, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 11, 2018

Completed
Last Updated

August 24, 2023

Status Verified

August 1, 2023

Enrollment Period

8 months

First QC Date

October 20, 2017

Last Update Submit

August 22, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • No change in the patient's parkinson's disease as measured by Unified Parkinson's Disease Rating Scale III

    UPDRS III is a clinical scale that measures the severity of the motor symptoms of Parkinson's Disease. No change is expected in the UPDRS III in the patients recruited from the start of the study to the end of the study.

    10 weeks

Secondary Outcomes (1)

  • An improvement by a minimum of 30% in the pain caused by Parkinson's Disease as measured by the King's Parkinson's Disease Pain Scale

    10 weeks

Study Arms (1)

Pain in PD Arm

EXPERIMENTAL

This arm will receive a total 10 sessions of TMS stimulation over 10 weeks. Pre and post intervention scales will be performed on week one and week 10.

Device: Repetitive Transcranial Magnetic Stimulation

Interventions

Transcranial magnetic stimulation (TMS) is a non-invasive method that uses electromagnetic induction to produce electric currents in the cortex that are strong enough to depolarise neurons sufficiently to trigger action potentials. It is an outpatient based procedure that when used in conjunction with a neuro-navigation system, specific cortical areas can be targeted for greater accuracy and efficacy. In clinical studies, TMS is delivered as trains of pulses (repetitive TMS, rTMS) to prolong its effects. While the exact mechanism of TMS-induced analgesia is unknown, it is thought to regulate the activity of the complex cortical and subcortical networks involved in the processing of painful signals and possibly strengthening the endogenous descending pain modulation system

Pain in PD Arm

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who have a diagnosis of Parkinson's Disease.
  • Medical treatment for the movement disorder to be optimized prior to the study.
  • Despite optimum medical therapy neuropathic pain is a major complaint for the patient:
  • A minimum total score on the King's Pain Scale of 12 or
  • A minimum subset domain score on Fluctuation-related Pain of 6 or
  • A minimum subset domain score on Nocturnal pain of 5 or
  • A minimum subset domain score on Radicular Pain of 3 or
  • No other cause for the pain is identified.
  • Age 18-80
  • Weekly average pain levels of 3/10 or more at the time of entry
  • The patient is capable of and willing to give informed consent for their participation.
  • The patient is capable of and willing to fill in a daily Pain diary during the study.

You may not qualify if:

  • Patients will be excluded from the trial if they:
  • Are suffering from pain not attributable from Parkinson's Disease
  • Are suffering from any neurological or psychiatric disease that could interfere with provision of reliable data (dementia, major depression, drug abuse, alcoholism)
  • Are suffering from a rapidly progressing malignant disease or other systemic disease that is likely to significantly interfere with their participation in the study
  • Are candidates or have been listed for surgery or other major medical intervention requiring hospitalisation and/or rehabilitation (e.g., hip replacement).
  • Have a history of seizures or epilepsy,
  • Require high doses of medication known to lower the threshold for seizures (e.g., amitriptyline \> 100mg/d,
  • Have cerebral space occupying lesion,
  • Have a history of severe head injury (associated with a suspicion of brain injury, e.g. resulting in unconsciousness for over 24 hrs)
  • Have metal located in head (e.g. shrapnel, surgical clips, fragments from welding),
  • Have a cochlear implant,
  • Have a cardiac pacemaker in situ,
  • Have a deep brain or vagal nerve stimulator in situ,
  • Are pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Walton Centre NHS Foundation Trust

Liverpool, Mersey, L97LJ, United Kingdom

Location

MeSH Terms

Conditions

Parkinson DiseaseNeuralgiaPain

Interventions

Transcranial Magnetic Stimulation

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative DiseasesPeripheral Nervous System DiseasesNeuromuscular DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeutics

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 20, 2017

First Posted

November 22, 2017

Study Start

April 5, 2018

Primary Completion

December 11, 2018

Study Completion

December 11, 2018

Last Updated

August 24, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will not share

Locations